doi:10.1088/1748-605X/aba445engPrieto, E.Cardiel, M.J.Vispe, E.Idoipe, M.Garcia-Martin, E.Fraile, J.M.Polo, V.Mayoral, J.A.Pablo, L.E.Rodrigo, M.J.Dexamethasone delivery to the ocular posterior segment by sustained-release Laponite formulationART-2020-121787This paper presents a novel nanoformulation for sustained-release delivery of dexamethasone (DEX) to the ocular posterior segment using a Laponite (LAP) carrier - DEX/LAP 1:10 w w-1 formulation; 10 mg ml-1. In vivo ocular feasibility and pharmacokinetics after intravitreal (IV) and suprachoroidal (SC) administration in rabbit eyes are compared against IV administration of a DEX solution (1 mg ml-1). Thirty rabbit eyes were injected with the DEX/LAP formulation (15 suprachoroid/15 intravitreous). Ophthalmological signs were monitored at day 1 and at weeks 1-4-12-24 post-administration. Three eyes per sample time point were used to quantify DEX concentration using high-performance liquid chromatography-mass spectrometry. The ocular tissues'' pharmacokinetic parameters (lens, vitreous humour, choroid-retina unit and sclera) were studied. DEX/LAP was well tolerated under both administration methods. Peak intraocular DEX levels from the DEX/LAP were detected in the vitreous humour after both deliveries soon after administration. The vitreous area under the curve was significantly greater after both DEX/LAP deliveries (IV: 205 968.47; SC: 11 442.22 ng g-1 d-1) than after IV administration of the DEX solution (317.17 ng g-1 d-1). Intravitreal DEX/LAP delivery extended higher vitreous DEX levels up to week 24 (466.32 311.15 ng g-1). With SC delivery, DEX levels were detectable in the choroid-retina unit (12.04 20.85 ng g-1) and sclera (25.46 44.09 ng g-1) up to week 24. This study demonstrated the intraocular feasibility of both SC and IV administration of the DEX/LAP formulation. The LAP increased the intraocular retention time of DEX when compared with conventional solutions. DEX/LAP could be considered a biocompatible and useful sustained-release formulation for treating posterior-pole eye diseases.2020http://zaguan.unizar.es/record/9740210.1088/1748-605X/aba445http://zaguan.unizar.es/record/97402oai:zaguan.unizar.es:97402info:eu-repo/grantAgreement/ES/DGA/E37-17Rinfo:eu-repo/grantAgreement/ES/DGA-FEDER/Construyendo Europa desde Aragóninfo:eu-repo/grantAgreement/ES/ISCIII/M17-00213info:eu-repo/grantAgreement/ES/ISCIII/PI12-02285info:eu-repo/grantAgreement/ES/ISCIII/PI17-01726info:eu-repo/grantAgreement/ES/ISCIII/PI17-01946info:eu-repo/grantAgreement/ES/MINECO-AEI-FEDER/MAT2017-83858-C2-2Biomedical Materials 15, 6 (2020), 065021 [14 pp]byhttp://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccess